Table 3.
Patient characteristics of survivors and non‐survivors in the curative‐intent group
| Characteristic | Non‐survivors (n = 37) | Survivors (n = 13) | |
|---|---|---|---|
| Sex—no. (%) | |||
| Male | 21 (57) | 8 (62) | P = .764 |
| Female | 16 (43) | 5 (39) | |
| Age at time of allogeneic HSCT—y | |||
| Median (interquartile range) | 53 (39‐60) | 53 (36‐59) | P = .674 |
| Range | 18‐71 | 22‐62 | |
| Age at time of relapse—y | |||
| Median (interquartile range) | 53 (40‐60) | 53 (38‐60) | P = .707 |
| Range | 19‐74 | 22‐62 | |
| Bone marrow blast count at time of relapse—% (n = 46) | |||
| Median (interquartile range) | 20 (14‐51) | 22 (8‐49) | P = .745 |
| Range | 1‐72 | 0‐74 | |
| No data | 3 | 1 | |
| Reinduction therapy—no. (%) | |||
| No reinduction therapy | 1 (3) | 1 (8) | |
| Hypomethylating therapy only | 3 (8) | 0 (0) | |
| High‐dose chemotherapy | 13 (35) | 9 (69) | |
| Reduce/stop immunosuppressants | 20 (54) | 3 (23) | |
| Reinduction therapy—no. (%) | |||
| No/low‐intensity therapy | 24 (65) | 4 (31) | P = .035 |
| High‐intensity | 13 (35) | 9 (69) | |
| Outcome after reinduction therapy—no. (%) | |||
| CR | 11 (30) | 11 (85) | P = .001 |
| No CR | 26 (70) | 2 (15) | |
| Hypomethylating agents—no. (%) | |||
| Yes | 7 (19) | 3 (23) | P = .533 |
| No | 29 (81) | 10 (77) | |
| No data | 1 | ||
| Consolidation therapy | |||
| No consolidation therapy | 29 (78) | 4 (31) | P = .003 |
| Consolidation therapy | 8 (22) | 9† (69) | |
| Time between HSCT and relapse—wk | |||
| Median (interquartile range) | 21 (12‐46) | 21 (17‐59) | P = .479 |
| Range | 5‐142 | 11‐187 | |
| Early vs late relapse—no. (%) | |||
| Early (<3 mo) | 10 (27) | 1 (8) | P = .144 |
| Late (≥3 mo) | 27 (73) | 12 (92) | |
†
Two received a second allogeneic HSCT with a different donor, the other patients DLI.